



1645  
#10  
By  
7-19-02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	July 10, 2002
<b>INFORMATION DISCLOSURE STATEMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231		Attorney Docket	STAN-193
		First Named Inventor	KIRKEGAARD, KARLA
		Application Number	09/863,841
		Confirmation No.	8970
		Filing Date	May 22, 2001
		Group Art Unit	1645
		Examiner Name	Unsigned
		Title:	"INHIBITORS OF VIRAL INFECTION"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-193 may be charged thereon.


Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 10, 2002

By:   
Carol L. Francis  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\DOCUMENT\STAN (Stanford)\193\IDS Statement.doc

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/863,841
		Filing Date	May 22, 2001
		First Named Inventor	Kirkegaard, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet 2 of 4		Attorney Docket Number	STAN-193

<b>OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DIAMOND, et al. "Clustered charged-to-alanine mutagenesis of poliovirus RNA-dependent RNA polymerase yields multiple temperature-sensitive mutants defective in RNA synthesis", <i>J. Virology</i> , (1994) Vol. 68(2): 863-876.	
		DOMINGO, et al. "Basic concepts in RNA virus evolution", <i>FASEB</i> , (1996) Vol. 10: 859-864.	
		DOUBLIÉ, et al. "The mechanism of action of T7 DNA polymerase", <i>Curr. Opin. Struct. Biol.</i> , (1998) Vol. 8: 704-712.	
		DOWNING, et al. "Tubulin and microtubule structure", <i>Curr. Opin. Cell Biol.</i> , (1998) Vol. 10: 16-22.	
		GRUN, et al. "Dissociation of NS5 from Cell Fractions Containing West Nile Virus-Specific Polymerase Activity", <i>J. Virol.</i> , (1987) Vol. 61: 3641-3644.	
		GYURIS, et al. "Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2", <i>Cell</i> , (1993) Vol. 79: 1-10.	
		HANSEN, et al. "Structure of the RNA-dependent RNA polymerase of poliovirus", <i>Structure</i> , (1997) Vol. 5: 1109-1122.	
		HOPE, et al. "Genetic Dissection of Interaction between Poliovirus #D polymerase and Viral Protein 3AB", <i>J. Virol.</i> , (1997) Vol. 71: 9490-9498.	
		JACOBO-MOLINA, et al. "Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA", <i>Proc. Natl. Acad. Sci. USA</i> , (1993) Vol. 90: 6320-6324.	
		JANIN, et al. "Protein-protein interaction at crystal contacts", <i>Proteins</i> , (1995) Vol. 23: 580-587.	
		KAO, et al. "Brome Mosaic Virus RNA Replication Proteins 1a and 2a Form a Complex In Vitro", <i>J. Virol.</i> , (1992) Vol. 66: 6322-6329.	
		KIRKEGAARD. "Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA", <i>J. Virology</i> , (1990) Vol. 64(1): 195-206.	
		KOIKE, et al. "Transgenic mice susceptible to poliovirus", <i>Proc. Natl. Acad. Sci. USA</i> , (1991) Vol. 88: 951-955.	
		LEDLEY. "Pharmaceutical approach to somatic gene therapy", <i>Pharm. Res.</i> , (1996) Vol. 13(11): 1595-1614.	
		LEMM, et al. "Assembly of functional sindbis virus RNA replication complexes: Requirement for coexpression of P123 and P34", <i>J. Virology</i> , (1993) Vol. 67(4): 1905-1915.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/863,841
		Filing Date	May 22, 2001
		First Named Inventor	Kirkegaard, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet 3 of 4		Attorney Docket Number	STAN-193

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LESBURG, et al. "Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site", <i>Nat. Struct. Biol.</i> , (1999) Vol. 6(10): 937-943.	
		MARKOWITZ, et al. "Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor", <i>J. Virology</i> , (1995) Vol. 69(2): 701-706.	
		MCBRIDE, et al. "Human protein Sam68 relocation and interaction with poliovirus RNA polymerase in infected cells", <i>Proc. Natl. Acad. Sci. USA</i> , (1996) Vol. 93: 2296-2301.	
		MOLLA, et al. "Ordered accumulation of mutations in HIV protease confers resistance to ritonavir", <i>Nature Medicine</i> , (1996) Vol. 2(7): 760-766.	
		NOGALES, et al. "High-resolution model of the microtubule", <i>Cell</i> , (1999) Vol. 96:79-88.	
		NUGENT, et al. "Functional coupling between replication and packaging of poliovirus replicon RNA", <i>J. Virology</i> , (1999) Vol. 73(1): 427-435.	
		PATA, et al. "Functional Oligomerization of Poliovirus RNA-dependent RNA Polymerase", <i>RNA</i> , (1995) Vol. 1: 466-477.	
		PAUL, et al. "Studies with poliovirus polymerase 3D <sup>pol</sup> ", <i>J. Biol. Chem.</i> , (1994) Vol. 269(46): 29173-29181.	
		PAVLETICH, et al. "Crystal Structure of a Five-Finger GLI-DNA Complex: New Perspectives on Zinc Fingers", <i>Science</i> , (1993) Vol. 216: 1701-1707.	
		PLOTCH, et al. "Purification and properties of poliovirus RNA polymerase expressed in <i>Escherichia coli</i> ", <i>J. Virology</i> , (1989) Vol. 63(1): 216-225.	
		POCH, et al. "Identification of four conserved motifs among the RNA-dependent polymerase encoding elements", <i>The EMBO J.</i> , (1989) Vol. 8(12): 3867-3874.	
		REN, et al. "Transgenic mice expressing a human poliovirus receptor: A new model for poliomyelitis", <i>Cell</i> , (1990) Vol. 63: 353-362.	
		SARNOW, et al. "Role of 3'-end sequences in infectivity of poliovirus transcripts made in vitro", <i>J. Virology</i> , Vol. 63(1): 467-470.	
		SCHLESINGER, et al. "Replication of yellow fever virus in the mouse central nervous system: Comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain", <i>J. Gen. Virology</i> , (1996) Vol. 77: 1277-1285.	
		SHERMAN, et al. "Pathogenesis of encephalitis induced in newborn mice by virulent and avirulent strains of sindbis virus", <i>J. Virology</i> , (1990) Vol. 64(5): 2041-2046.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
		Application Number	09/863,841
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	May 22, 2001
		First Named Inventor	Kirkegaard, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	STAN-193
Sheet	4	of	4

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		STEITZ, et al. "DNA polymerases: Structural diversity and common mechanisms", <i>J. Biol. Chem.</i> , (1999) Vol. 274(25): 17395-17398.	
		TAN, et al. "Recombinant dengue type 1 virus NS5 protein expressed in <i>Escherichia coli</i> exhibits RNA-dependent RNA polymerase activity", <i>Virology</i> , (1996) Vol. 216: 317-325.	
		WONG, et al. "A double-filter method for nitrocellulose-filter binding: Application to protein-nucleic acid interactions", <i>Proc. Natl. Acad. Sci. USA</i> (1993) Vol. 90:5428-5432.	
		YANG, et al. "Protein-peptide interactions analyzed with the yeast two-hybrid system", <i>Nucleic Acids Res.</i> , (1995) Vol. 23(7): 1152-1156.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
				Application Number	09/863,841
		Filing Date	May 22, 2001		
		First Named Inventor	Kirkegaard, et al.		
		Group Art Unit	1645		
		Examiner Name	Unassigned		
		Attorney Docket Number	STAN-193		
Sheet	1	of	4		

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,025,388		Cramer, III, et al.	06-18-1991	
		5,307,287		Cramer, III, et al.	04-26-1994	
		5,434,796		Weininger	07-18-1995	
		5,436,850		Eisenberg, et al.	07-25-1995	
		5,526,281		Chapman, et al.	06-11-1996	
		5,884,230		Srinivasan, et al.	03-16-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AGO, et al. "Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus", <i>Structure Fold Des.</i> , (1999) Vol. 7: 1417-1426.	
		ANDINO, et al. "Engineering poliovirus as a vaccine vector for the expression of diverse antigens", <i>Science</i> , (1994) Vol. 265: 1448-1451.	
		BRESSANELLI, et al. "Crystal structure of the RNA-dependent RNA polymerase of hepatitis C", <i>PNAS</i> , (1999) Vol. 96(23): 13034-13039.	
		CALOS. "The potential of extrachromosomal replicating vectors for gene therapy", <i>Trends in Genetics</i> , (1996) Vol. 12(11): 463-466.	
		COLAS, et al. "Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2", <i>Nature</i> , (1996) Vol. 380: 548-550.	
		COOPER. "Noninfectious gene transfer and expression systems for cancer gene therapy", <i>Seminars in Oncology</i> , (1996) Vol. 23(1): 172-187.	
		DELARUE, et al. "An attempt to unify the structure of polymerases", <i>Protein Engineering</i> , (1990) Vol. 3(6): 461-467.	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.